Hugel Inc (145020) - Total Liabilities

Latest as of June 2026: ₩104.15 Billion KRW ≈ $70.58 Million USD

Based on the latest financial reports, Hugel Inc (145020) has total liabilities worth ₩104.15 Billion KRW (≈ $70.58 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Hugel Inc (145020) long-term investment share to see how much of total assets are deployed in long-term investments.

Hugel Inc - Total Liabilities Trend (2014–2025)

This chart illustrates how Hugel Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Hugel Inc asset portfolio.

Hugel Inc Competitors by Total Liabilities

The table below lists competitors of Hugel Inc ranked by their total liabilities.

Company Country Total Liabilities
Shenzhen Sinexcel Electric Co Ltd
SHE:300693
China CN¥1.99 Billion
Ashtrom Group Ltd
TA:ASHG
Israel ILA18.15 Billion
Guangdong No2 Hydropower Engineering Co Ltd
SHE:002060
China CN¥125.45 Billion
Ennoconn Corp
TW:6414
Taiwan NT$119.65 Billion
The Jammu & Kashmir Bank Limited
NSE:J&KBANK
India Rs1.72 Trillion
Ningbo ZhongDa Leader Intelligent Transmission Co Ltd
SHE:002896
China CN¥649.06 Million
NagaCorp Ltd
F:N9J
Germany €367.58 Million
NCC AB (publ)
ST:NCC-B
Sweden Skr25.25 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Hugel Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Hugel Inc balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 7.55 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.10 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.09 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hugel Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hugel Inc (2014–2025)

The table below shows the annual total liabilities of Hugel Inc from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩96.68 Billion
≈ $65.52 Million
-1.98%
2024-12-31 ₩98.63 Billion
≈ $66.84 Million
-34.06%
2023-12-31 ₩149.57 Billion
≈ $101.36 Million
-41.95%
2022-12-31 ₩257.67 Billion
≈ $174.62 Million
+10.75%
2021-12-31 ₩232.65 Billion
≈ $157.66 Million
+10.96%
2020-12-31 ₩209.67 Billion
≈ $142.09 Million
+7.42%
2019-12-31 ₩195.19 Billion
≈ $132.28 Million
+2.44%
2018-12-31 ₩190.55 Billion
≈ $129.13 Million
+52.17%
2017-12-31 ₩125.22 Billion
≈ $84.86 Million
+201.71%
2016-12-31 ₩41.50 Billion
≈ $28.13 Million
+61.33%
2015-12-31 ₩25.73 Billion
≈ $17.43 Million
-41.58%
2014-12-31 ₩44.04 Billion
≈ $29.84 Million
--

About Hugel Inc

KQ:145020 Korea Biotechnology
Market Cap
$1.72 Billion
₩2.54 Trillion KRW
Market Cap Rank
#6704 Global
#163 in Korea
Share Price
₩235500.00
Change (1 day)
+1.51%
52-Week Range
₩214000.00 - ₩313500.00
All Time High
₩388000.00
About

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more